PanCAN Statement on Positive Overall Survival Results from Revolution Medicines Phase III Trial at ASCO
Jun 1, 2026 - By Julie Vasquez The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following…
Read the full articleYou might also wanna read
Pancreatic cancer drug daraxonrasib nearly doubles median survival in clinical trials
The pancreatic-cancer drug could be the first of an entirely new class of treatments
economist.com·8d ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
npr.org·1mo ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
cnbc.com·1mo ago
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend.
fox26houston.com·1mo ago
New daily pill daraxonrasib nearly doubles survival time for advanced pancreatic cancer patients
The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemothe
to.pbs.org·1mo ago
Experimental Drug Daraxonrasib Shows First Major Survival Benefit for Pancreatic Cancer Patients
The new strategy also holds promise for lung and colon tumors. Here’s how scientists discovered it.
nytimes.com·27d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.